- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03870126
Dose Effect of a Plant Extract on Fatigue
14. januar 2020 oppdatert av: PepsiCo Global R&D
Effects of Two Doses of a Plant Extract on Mental and Physical Fatigue
Test the short-term effects of the acute consumption of two separate beverages containing different concentrations of polyphenols, a beverage containing 75 mg of caffeine and a flavored placebo beverage on mental energy and physical performance
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
28
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Georgia
-
Athens, Georgia, Forente stater, 30602
- University of Georgia
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 49 år (Voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- 18-49 years of age
- Self-report of good health
- Physical activity requirement: Recreationally active (exercise ≥3 times per week for >30 minutes per session; both cyclists and non-cyclists may enroll)
Exclusion Criteria:
- Under the care of a physician
- Visual impairment that cannot be corrected with glasses or contact lenses
- Inability to perform high intensity exercise (defined perceptually as exercise that feels at least "hard" and this is usually quantified using the Borg 6 to 20 scale. High intensity cycling exercise is defined objectively as exercise causing a high heart rate, defined as a heart rate that is equal to or greater than 70% of heart rate reserve.)
- Inability to adequately perform the cognitive tasks (i.e., cannot complete the task due to -inability to understand instructions or >50% incorrect responses)
- Presence of current or chronic gastrointestinal, sleep or psychiatric disorder
- Pregnant/lactating
- Current smoker
- Report illegal drug use
- Report hypersensitivity to caffeine
- Food allergies/intolerances/sensitivities (including coffee or related foods/beverages/products)
- Current use of dietary supplements, or prescription medication except for oral contraceptives
- Unwillingness to abstain from over the counter medications (e.g. NSAIDS, allergy medications) and caffeine/coffee/foods high in polyphenols for 12 hours prior to the study
- Unwilling to refrain from consuming apple and grapefruit products on study days and 12 hours prior to test days.
- Participation in another clinical trial within the past 30 days or participation in another PepsiCo trial in the past 6 months
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Flavored Beverage Mix 1
Flavored still beverage
|
Consume one beverage at the beginning of each visit of the cross-over sequence
|
|
Eksperimentell: Flavored Beverage Mix 2
Flavored still beverage with polyphenols, concentration 1
|
Consume one beverage at the beginning of each visit of the cross-over sequence
|
|
Eksperimentell: Flavored Beverage Mix 3
Flavored still beverage with polyphenols, concentration 2
|
Consume one beverage at the beginning of each visit of the cross-over sequence
|
|
Eksperimentell: Flavored Beverage Mix 4
Flavored still beverage with caffeine
|
Consume one beverage at the beginning of each visit of the cross-over sequence
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Subjective mental energy: Cognitive test battery
Tidsramme: Baseline and 60 min post treatment
|
Changes in subjective measures of mental alertness and mental fatigue through computer administered cognitive test battery domains of short-term memory, attention and mood.
Tasks are word presentation, word recognition, picture presentation, picture recognition, Cognitive Demand Battery (CDB) serial 3 and serial 7 subtraction, and Bakan task/Rapid Visual Information Processing (RVIP).
Performance measures: % correct, % errors and response time in milliseconds.
|
Baseline and 60 min post treatment
|
|
Subjective mental energy: VAS for mental alertness
Tidsramme: Baseline and 60 min post treatment
|
Changes in subjective ratings of mental alertness following computer administered cognitively fatiguing tasks.
Visual Analog Scale (VAS) for mental alertness has the score range 0-100 (from not at all to extremely).
|
Baseline and 60 min post treatment
|
|
Subjective mental energy: VAS for motivation
Tidsramme: Baseline and 60 min post treatment
|
Changes in subjective ratings of motivation following computer administered cognitively fatiguing tasks.
Visual Analog Scale (VAS) for motivation has the score range 0-100 (from not at all to extremely).
|
Baseline and 60 min post treatment
|
|
Subjective mental energy: VAS for mental fatigue
Tidsramme: Baseline and 60 min post treatment
|
Changes in subjective ratings of fatigue following computer administered cognitively fatiguing tasks.
Visual Analog Scale (VAS) for fatigue has the score range 0-100 (from not at all to extremely).
|
Baseline and 60 min post treatment
|
|
Subjective mental and physical energy: VAS for mental and physical state and trait energy and fatigue (EFS State Scales)
Tidsramme: Baseline and 60 min post treatment
|
Changes in subjective ratings of mental alertness, motivation and fatigue following computer administered cognitively fatiguing tasks.
Mental and Physical State and Trait Energy and Fatigue Scales (EFS State Scales) consist of 12 VAS items to measure intensity of current feeling of physical energy and fatigue and mental energy and fatigue (3 sub-scales each).
Score range: The 3 items from each sub-scale are summed and scores for each sub-scale range from 0-300 (none to strongest).
|
Baseline and 60 min post treatment
|
|
Subjective mental energy: VAS for mood
Tidsramme: Baseline and 60 min post treatment
|
Changes in subjective ratings of mental alertness, motivation and fatigue following computer administered cognitively fatiguing tasks.
The Bond-Lader test uses 16 Visual Analog Scales (VAS) to measure different aspects of mood, with score range 0-100 for each scale (from absence of feeling to presence of feeling).
|
Baseline and 60 min post treatment
|
|
Subjective mental energy: VAS for caffeine symptoms
Tidsramme: Baseline and 60 min post treatment
|
Changes in subjective ratings of mental alertness, motivation and fatigue following computer administered cognitively fatiguing tasks.
Caffeine symptoms are measured on paper using 8 Visual Analog Scales (VAS) with score range 0-100 (from not at all to extremely).
|
Baseline and 60 min post treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Physical performance
Tidsramme: During the last 3 minutes of 23 min high intensity cycling exercise (10 x 1 min work intervals each followed by 1 min rest. No rest after final interval, 3 min max power from minutes 20-23.
|
Mean power output in a timed cycling trial following post-treatment cognitive test battery and caffeine symptom VAS.
|
During the last 3 minutes of 23 min high intensity cycling exercise (10 x 1 min work intervals each followed by 1 min rest. No rest after final interval, 3 min max power from minutes 20-23.
|
|
Physical Fatigue
Tidsramme: After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
|
Subjective categorical scale, score range 0-7, higher score indicates greater feeling of physical fatigue
|
After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
|
|
Alertness
Tidsramme: After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
|
Subjective categorical scale, score range 1-7, higher score indicates greater alertness meaning a greater feeling of energy
|
After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
|
|
Effort
Tidsramme: After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
|
Subjective categorical scale, Borg Ratings of Perceived Exertion (RPE) measures perception of effort, score range 6-20.
Higher score indicates greater effort.
17 or greater generally indicates maximal effort
|
After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
|
|
Quadriceps muscle pain
Tidsramme: After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
|
Subjective categorical scale with ratio-like properties, scale 0-10 with open-ended option for ratings greater than but proportional to 10. Higher scores indicate greater perception of pain in the quadriceps
|
After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Patrick J O'Connor, PhD, University of Georgia
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
29. januar 2019
Primær fullføring (Faktiske)
6. desember 2019
Studiet fullført (Faktiske)
6. desember 2019
Datoer for studieregistrering
Først innsendt
26. februar 2019
Først innsendt som oppfylte QC-kriteriene
8. mars 2019
Først lagt ut (Faktiske)
11. mars 2019
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
18. januar 2020
Siste oppdatering sendt inn som oppfylte QC-kriteriene
14. januar 2020
Sist bekreftet
1. januar 2020
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PEP-1807
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Ja
IPD-planbeskrivelse
IPD will be kept securely at U. Georgia for several years and can be accessed upon request by contacting Dr. Pat O'Connor (poconnor@uga.edu)
IPD-delingstidsramme
After publication
Tilgangskriterier for IPD-deling
Open access, upon request
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .